CC趋化因子配体20在肝细胞癌组织中的表达及其在肝细胞肝癌预后评估中作用的生物信息学分析

研究CC趋化因子配体20（CCL20）在肝细胞肝癌（LIHC）组织中的表达，并探讨其对LIHC患者预后的影响，阐述CCL20影响LIHC恶性行为的机制。

Bioinformatics analysis on CC chemokine ligand 20 expression in hepatocellular carcinoma tissue and its effect on prognostic assessment of liver hepatocellular carcinoma

To investigate the expression of CC chemokine ligand 20 （CCL20） in liver hepatocellular carcinoma（LIHC） tissue and explore its influence in the prognosis in the patients with LIHC， and to elucidate the mechanism of CCL20 affecting the malignant behavior of LIHC. Methods The mRNA expression levels and clinical data in cancer tissue and para-cancer tissue of the LIHC patients were obtained from The Cancer Genome Atlas （TCGA） and UCSC Xena platforms using Rstudio （4.03） software， and the differences in the CCL20 mRNA expression between the two kinds of tissues were compared，and these results were validated using GEPIA combined with GTEx data. Kaplan-Meier survival analysis and Cox regression analysis methods were used to analyze the relationship between the CCL20 mRNA expression level and the prognosis of LIHC patients. The correlation between the CCL20 expression level and alpha fetoprotein （AFP） level in the LIHC patients was analyzed by Pearson correlation analysis， and the area under receiver operating characteristic （ROC） curve（AUC）， Nomogram and correction curve were used to analyze the correlations between the CCL20 mRNA expression level and the clinical diagnosis and survival prediction in the patients with LIHC. GSEA enrichment analysis of the CCL20 mRNA correlation between the expression level expression in cancer tissue of the LIHC patients was performed using the TCGA database， and the correlation between the expression level of CCL20 mRNA and DNA copy-number alterations（CNA） and DNA methylation level were analyzed.